Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH|CAS 131287-39-3|DC Chemicals

Cas No.:	131287-39-3
Chemical Name:	Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH
Synonyms:	Fmoc-Asn(Ac3AcNH-beta-Glc)-OH;N-(9-Fluorenylmethyloxycarbonyl)-N'-(2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-beta-D-glucopyranosyl)-L-asparagine;(2S)-4-[[(2R,3R,4R,5S,6R)-3-acetamido-4,5-diacetyloxy-6-(acetyloxymethyl)oxan-2-yl]amino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-oxobutanoic acid;Fmoc-Asn(GlcNAc(Ac)?-β-D)-OH;Fmoc-Asn(GlcNAc(Ac)3-b-D)-OH;Fmoc-Asn(GlcNAc(Ac)₃-β-D)-OH;Fmoc-L-Asn(GlcNAc(Ac)3-beta)-OH;Fmoc-L-Asn(GlcNAc4)-OH;Fmoc-L-Asn (β-D-GlcNAc(Ac)3)-OH;Fmoc-L-Asn((Ac)3-β-D-GlcNAc)-OH;N-α-(fluorenylmethoxycarbonyl)-N-γ-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl)-L-asparagine;GLCNAC L-ASPARAGINE;FMOC-L-ASN(GLCNAC)-OH;FMOC-ASN(GLCNAC(AC)3-B)-OH;Fmoc-Asn(GlcNAc(Ac)-β-D)-OH;FMoc-Asn(β-D-GlcNAc(Ac)3)-OH;Fmoc-L-Asn(GlcNAc(Ac)3-b)-OH;Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH;Fmoc-Asn(GlcNAc(Ac)3-β-D)-OH;FMoc-Asn(GlcNAc(Ac)3-b-D)-OH;FMOC-ASN(AC3ACNH-BETA-GLC)-OH;MFCD00237079;CS-0169635;EX-A3853;Fmoc-Asn(GlcNAc(Ac)3-;131287-39-3;AKOS025294293;A930302;fmoc-asn(glcnac(ac)3-beta-d)-oh;(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-((2R,3R,4R,5S,6R)-3-acetamido-4,5-diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-ylamino)-4-oxobutanoic acid;Fmoc-Asn[GlcNAc(Ac)3-beta-D]-OH;AS-48994;SCHEMBL6044028;(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-(((2R,3R,4R,5S,6R)-3-acetamido-4,5-diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)amino)-4-oxobutanoic acid;DTXSID40442309;FD21194;HY-141464;glcnac l-asparagine;L-Asparagine, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl]-;N--Fmoc-N--(2-acetamido-2-deoxy-3,4,6-tri-O-acetyl--D-glucopyranosyl)-L-asparagine;Fmoc-L-Asn((Ac)3-beta-D-GlcNAc)-OH, >=95% (HPLC);Fmoc-Asn(GlcNAc(Ac)--D)-OH;N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-gamma-(2-acetamido-2deoxy-3,4,6-tri-O-acetyl-beta-D-galactopyranosyl)-L-asparagin (Fmoc-L-Asn(GlcNAc4)-OH);A-D)-OH
SMILES:	CC(N[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H](O[C@H]1NC(C[C@H](NC(OCC2C3=CC=CC=C3C4=CC=CC=C42)=O)C(O)=O)=O)COC(C)=O)=O
Formula:	C₃₃H₃₇N₃O₁₃
M.Wt:	683.65918
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.